| Ytd | -97.98% | |
| 1y | -99.23% |
| Open | 0.02 | Prev Close | 0.01 | Low | 0.01 | High | 0.02 | Mkt Cap | 885.69K |
| Vol | 3.06M | Avg Vol | 19.98M | EPS | -0.23 | P/E | -0.05 | Forward P/E | -0.76 |
| Beta | 0.88 | Short Ratio | 1.89 | Inst. Own | 76.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 0.27 | 200-d Avg | 0.95 | 1yr Est | 9.00 |
IOBT News
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received an average rating of "Reduce" from th
Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transce
Major M&A deals this week include: Eli Lilly's $7.8 billion purchase of Centessa Pharmaceuti
US stocks rise on Tuesday, with NASDAQ up 2% and Dow up 1.37%. Communication services shares gain 2.
US stocks higher, Dow up 0.90%, Nasdaq up 1.61%. Communication services gained 1.8%, utilities fell
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has received a consensus rating of "Reduce" from t
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant drop in short inte
IO Biotech, Inc. (IOBT) witnesses a hammer chart pattern, indicating support found by the stock afte
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) was the target of a significant increase in short
Raymond James engaged as financial advisor Reduction in force implemented NEW YORK, Jan. 30, 2026 (G
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceu
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 bl
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceu
IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou
IO Biotech, Inc. (NASDAQ: IOBT - Get Free Report) has earned an average rating of "Hold" from the si
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data high
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceu
Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonst
Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survi
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The comp
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday'
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data fr
Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of I
IO Biotech, Inc. (NASDAQ:IOBT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9,
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmace
IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is
On Wednesday, 220 stocks hit new 52-week lows.